Sign In
Buy AZN
$181.02
+4.59 (+2.60%)
At Close: Jun 23, 2026
AstraZeneca Stock Declines 6% in 3 Months: Time to Buy the Dip?
10:05am, Wednesday, 21'st May 2025
AZN's key drugs like Lynparza, Tagrisso, Imfinzi, Ultomiris and Fasenra are likely to drive sales in 2025.
WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to eliminate cancer as a cause of death with new data across its diverse, industry-leading portfolio and pipeline at the American S
3 Promising Growth Stocks You Can Buy for Less Than $100
09:41pm, Tuesday, 20'th May 2025
Investing in growth stocks is a great way to grow your portfolio in the long run. But it can be difficult to predict which ones will take off in value and which one's won't.
WILMINGTON, Del.--(BUSINESS WIRE)--Positive full results from the BATURA Phase IIIb trial showed AstraZeneca's anti-inflammatory reliever rescue therapy, AIRSUPRA (albuterol/budesonide), demonstrated
35 Barron's Pro-Picks: One Ideal May DiviDog
04:51am, Sunday, 18'th May 2025
Barron's interviewed eleven financial industry Roundtable-pros who tapped 65 predictions. Six non-ADR foreign-stocks and four mutual funds were dropped by YCharts screens of active US listings, leavin
Latest preliminary data show continued promising clinical activity in NHL patients, with two complete responses (CR), three partial responses (PR), and three stable disease (SD) as best clinical respo
Dr. Scott Gottlieb: What to expect from President Trump's executive order to lower drug prices
12:36pm, Monday, 12'th May 2025
Scott Gottlieb, former FDA commissioner, joins CNBC's 'Squawk on the Street' to discuss how the White House may plan to cut drug prices.
How Much Upside is Left in Astrazeneca (AZN)? Wall Street Analysts Think 27.89%
11:00am, Friday, 09'th May 2025
The consensus price target hints at a 27.9% upside potential for Astrazeneca (AZN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estima
WILMINGTON, Del.--(BUSINESS WIRE)--Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca's IMFINZI® (durvalumab) plus standard-of-care BCG inducti
AstraZeneca's Imfinzi delays bladder cancer return in high-risk patients
02:51am, Friday, 09'th May 2025
AstraZeneca PLC (LSE:AZN) has reported encouraging results from a late-stage trial of its cancer immunotherapy Imfinzi, which significantly extended the time patients with early-stage bladder cancer
Tempus AI Stock: Time to Double Down or Cut and Run?
07:46am, Thursday, 08'th May 2025
Tempus AI NASDAQ: TEM is an interesting AI story that operates a platform and library for diagnosis and drug discovery. The platform aids physicians by enabling personalized care for hard-to-treat ill
AstraZeneca and GSK slide as Trump and RFK appoint new FDA vaccine chief
05:53am, Wednesday, 07'th May 2025
Shares in AstraZeneca PLC (LSE:AZN) and GSK PLC (LSE:GSK, NYSE:GSK) on the back of an appointment by Donald Trump and his health secretary Robert F Kennedy Jnr of a key position at the US drug r
AZN or ARGX: Which Is the Better Value Stock Right Now?
12:46pm, Tuesday, 06'th May 2025
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Astrazeneca (AZN) or argenex SE (ARGX). But which of these two stocks offers value investors
AstraZeneca's Breztri meets main goals of late-stage asthma trials
02:20am, Friday, 02'nd May 2025
Anglo-Swedish drugmaker AstraZeneca on Friday said its inhaler therapy Breztri Aerosphere met all the main goals of two late-stage trials in patients with uncontrolled asthma.
AstraZeneca has plenty coming down the pipeline to appease the bears
08:23am, Wednesday, 30'th Apr 2025
AstraZeneca PLC (LSE:AZN) investors looking beyond the short-term noise of Medicare reform and currency headwinds may want to focus on a growing pipeline of clinical catalysts and a valuation that UB
